Vanda Pharmaceuticals Stock Performance
| VNDA Stock | USD 4.79 0.02 0.42% |
The entity has a beta of 0.39, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Vanda Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Vanda Pharmaceuticals is expected to be smaller as well. Vanda Pharmaceuticals right now has a risk of 2.47%. Please validate Vanda Pharmaceuticals expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to decide if Vanda Pharmaceuticals will be following its existing price patterns.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Vanda Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong fundamental indicators, Vanda Pharmaceuticals is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return (3.05) | Five Day Return (5.36) | Year To Date Return (1.04) | Ten Year Return (50.10) | All Time Return (50.72) |
1 | Disposition of 412 shares by Kevin Moran of Vanda Pharmaceuticals at 6.3 subject to Rule 16b-3 | 01/30/2025 |
2 | Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025 | 02/05/2025 |
3 | Acquisition by Timothy Williams of 125000 shares of Vanda Pharmaceuticals subject to Rule 16b-3 | 02/18/2025 |
4 | Acquisition by Kevin Moran of 2000 shares of Vanda Pharmaceuticals at 4.3894 subject to Rule 16b-3 | 02/21/2025 |
5 | Vanda Pharmaceuticals announces the publication of an article titled Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S | 02/24/2025 |
6 | Acquisition by Polymeropoulos Mihael Hristos of 10000 shares of Vanda Pharmaceuticals at 4.464 subject to Rule 16b-3 | 02/25/2025 |
7 | Insider Buying Mihael Polymeropoulos Acquires Shares of Vanda Pharmaceuticals Inc | 02/26/2025 |
8 | Insider Buying Mihael Polymeropoulos Acquires Additional Shares of Vanda Pharmaceuticals Inc | 02/27/2025 |
9 | US High Growth Tech Stocks With Strong Potential | 02/28/2025 |
10 | Acquisition by Polymeropoulos Mihael Hristos of 10000 shares of Vanda Pharmaceuticals at 4.705 subject to Rule 16b-3 | 03/03/2025 |
11 | Disposition of 15520 shares by Joakim Wijkstrom of Vanda Pharmaceuticals at 4.76 subject to Rule 16b-3 | 03/04/2025 |
12 | Acquisition by Polymeropoulos Mihael Hristos of 5000 shares of Vanda Pharmaceuticals at 5.01 subject to Rule 16b-3 | 03/05/2025 |
13 | Acquisition by Polymeropoulos Mihael Hristos of 5000 shares of Vanda Pharmaceuticals at 5.02 subject to Rule 16b-3 | 03/06/2025 |
14 | Disposition of 7966 shares by Kevin Moran of Vanda Pharmaceuticals at 6.2573 subject to Rule 16b-3 | 03/17/2025 |
15 | HC Wainwright maintains 20 target on Vanda Pharmaceuticals stock - Investing.com India | 03/19/2025 |
| Begin Period Cash Flow | 136.3 M |
Vanda |
Vanda Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 483.00 in Vanda Pharmaceuticals on December 24, 2024 and sell it today you would lose (6.00) from holding Vanda Pharmaceuticals or give up 1.24% of portfolio value over 90 days. Vanda Pharmaceuticals is currently generating 0.0094% in daily expected returns and assumes 2.4692% risk (volatility on return distribution) over the 90 days horizon. In different words, 22% of stocks are less volatile than Vanda, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Vanda Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vanda Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Vanda Pharmaceuticals, and traders can use it to determine the average amount a Vanda Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0038
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | VNDA |
Estimated Market Risk
| 2.47 actual daily | 22 78% of assets are more volatile |
Expected Return
| 0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Vanda Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vanda Pharmaceuticals by adding Vanda Pharmaceuticals to a well-diversified portfolio.
Vanda Pharmaceuticals Fundamentals Growth
Vanda Stock prices reflect investors' perceptions of the future prospects and financial health of Vanda Pharmaceuticals, and Vanda Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vanda Stock performance.
| Return On Equity | -0.0302 | ||||
| Return On Asset | -0.0364 | ||||
| Profit Margin | (0.09) % | ||||
| Operating Margin | (0.23) % | ||||
| Current Valuation | (83.53 M) | ||||
| Shares Outstanding | 58.31 M | ||||
| Price To Earning | 24.83 X | ||||
| Price To Book | 0.52 X | ||||
| Price To Sales | 1.40 X | ||||
| Revenue | 198.77 M | ||||
| Gross Profit | 230.1 M | ||||
| EBITDA | (40.66 M) | ||||
| Net Income | (18.9 M) | ||||
| Cash And Equivalents | 440.86 M | ||||
| Cash Per Share | 7.79 X | ||||
| Total Debt | 12.36 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 5.62 X | ||||
| Book Value Per Share | 9.28 X | ||||
| Cash Flow From Operations | (15.76 M) | ||||
| Earnings Per Share | (0.19) X | ||||
| Market Capitalization | 314.86 M | ||||
| Total Asset | 656.2 M | ||||
| Retained Earnings | (174.29 M) | ||||
| Working Capital | 338.91 M | ||||
| Current Asset | 166.55 M | ||||
| Current Liabilities | 51.32 M | ||||
About Vanda Pharmaceuticals Performance
By analyzing Vanda Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Vanda Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Vanda Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Vanda Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 38.50 | 36.57 | |
| Return On Tangible Assets | (0.03) | (0.04) | |
| Return On Capital Employed | (0.07) | (0.08) | |
| Return On Assets | (0.03) | (0.03) | |
| Return On Equity | (0.04) | (0.04) |
Things to note about Vanda Pharmaceuticals performance evaluation
Checking the ongoing alerts about Vanda Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vanda Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 198.77 M. Net Loss for the year was (18.9 M) with profit before overhead, payroll, taxes, and interest of 230.1 M. | |
| Vanda Pharmaceuticals currently holds about 440.86 M in cash with (15.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.79, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Vanda Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 77.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from news.google.com: HC Wainwright maintains 20 target on Vanda Pharmaceuticals stock - Investing.com India |
- Analyzing Vanda Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vanda Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Vanda Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vanda Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vanda Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vanda Pharmaceuticals' stock. These opinions can provide insight into Vanda Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Vanda Stock analysis
When running Vanda Pharmaceuticals' price analysis, check to measure Vanda Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vanda Pharmaceuticals is operating at the current time. Most of Vanda Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vanda Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vanda Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vanda Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |